Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors
No obvious weight loss yet- but again its only been 3 weeks so I am sure this will change over time
Individuals with a history of pancreatitis, diabetic retinopathy, or thyroid tumors might face increased risks and side effects, making them less ideal candidates
Impaired Biosynthesis: Chronic hyperglycaemia suppresses GCLC and GSS, the two enzymes that synthesise new glutathione within cells
Not everyone will see the same effects
Those aged 18 or over, with a BMI of 30 or higheror a BMI of 27 or higher with a weight-related condition like type 2 diabetes or hypertensionmay be eligible
